Abstracts tagged "anti-dsDNA and nephritis"

Abstract Number: 2645 • 2017 ACR/ARHP Annual Meeting
The Internalization of DNA-Antibodies By Podocytes during Lupus Nephritis
Anja Römer-Hillmann¹, Elisabeth Jung², Annika Engbers¹, Marcel Reinhardt¹, Hedda Wardemann³, Thomas Pap⁴ and Annett Jacobi⁵, ¹Institute of Musculoskeletal Medicine, University Hospital Muenster, Muenster, Germany, ²Department of Internal Medicine D, Rheumatology, University Hospital Muenster, Muenster, Germany, ³Deutsches Krebsforschungszentrum, Heidelberg, Germany, ⁴Institute for Musculoskeletal Medicine, University Hospital Muenster, Muenster, Germany, ⁵Internal Medicine, Ruppiner Kliniken GmbH, Neuruppin, Germany
Background/Purpose: Podocytes are postmitotic visceral epithelial cells, located at the Bowmans capsule of the kidney building up the slit diaphragm with their foot processes to…
Abstract Number: 2901 • 2015 ACR/ARHP Annual Meeting
Anti-dsDNA Antibodies Measured By Chemiluminescent Immunoassay Show Strong Association with Active Lupus Nephritis
Gabriella Lakos¹, John G. Hanly², Peter Martis¹, Chelsea Bentow¹, Milagros Garcia³, Odette Viñas³, Gerard Espinosa⁴, Ricard Cervera⁴ and Michael Mahler⁵, ¹Research, Inova Diagnostics, San Diego, CA, ²Rheumatology, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ³Immunology, Hospital Clinic of Barcelona, Barcelona, Spain, ⁴Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Spain, ⁵Inova Diagnostics, San Diego, CA
Background/Purpose: Anti-dsDNA antibodies support the diagnosis of systemic lupus erythematosus (SLE), and their quantification is useful for the assessment of lupus nephritis (LN) and the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].